{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inflammation+Associated+With+Cataract+Surgery",
    "query": {
      "condition": "Inflammation Associated With Cataract Surgery"
    },
    "page_size": 10
  },
  "pagination": {
    "page": 1,
    "page_size": 10,
    "total_count": 18,
    "total_pages": 2,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Inflammation+Associated+With+Cataract+Surgery&page=2&page_size=10",
    "previous_page_url": null
  },
  "source": "remote",
  "last_synced_at": "2026-06-11T05:35:17.383Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02006888",
      "title": "The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Inflammation",
        "Cataracts"
      ],
      "interventions": [
        {
          "name": "IBI-10090",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ICON Bioscience Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 394,
      "start_date": "2014-01",
      "completion_date": "2014-10",
      "has_results": true,
      "last_update_posted_date": "2018-04-23",
      "last_synced_at": "2026-06-11T05:35:17.383Z",
      "location_count": 1,
      "location_summary": "Lancaster, California",
      "locations": [
        {
          "city": "Lancaster",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02006888"
    },
    {
      "nct_id": "NCT01606735",
      "title": "Efficacy and Safety of IBI-10090 in Ocular Surgery Patients",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Inflammation Associated With Cataract Surgery"
      ],
      "interventions": [
        {
          "name": "IBI-10090",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ICON Bioscience Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 172,
      "start_date": "2012-04",
      "completion_date": "2013-03",
      "has_results": true,
      "last_update_posted_date": "2014-09-22",
      "last_synced_at": "2026-06-11T05:35:17.383Z",
      "location_count": 2,
      "location_summary": "Hemet, California • Temecula, California",
      "locations": [
        {
          "city": "Hemet",
          "state": "California"
        },
        {
          "city": "Temecula",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01606735"
    },
    {
      "nct_id": "NCT03499873",
      "title": "Clinical Endpoint Study of Nepafenac 0.3% Opthalmic Suspension",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Nepafenac 0.3% Oph Susp",
          "type": "DRUG"
        },
        {
          "name": "Placebos",
          "type": "DRUG"
        },
        {
          "name": "Nepafenac 0.3% Oph Susp (reference)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Actavis Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 448,
      "start_date": "2018-03-28",
      "completion_date": "2018-12-18",
      "has_results": true,
      "last_update_posted_date": "2021-02-16",
      "last_synced_at": "2026-06-11T05:35:17.383Z",
      "location_count": 1,
      "location_summary": "Dallas, Texas",
      "locations": [
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03499873"
    },
    {
      "nct_id": "NCT00333918",
      "title": "Safety/Efficacy of Bromfenac Ophthalmic Solution for Ocular Inflammation and Pain Associated With Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Pain",
        "Inflammation"
      ],
      "interventions": [
        {
          "name": "bromfenac ophthalmic solution",
          "type": "DRUG"
        },
        {
          "name": "placebo comparator",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bausch & Lomb Incorporated",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 522,
      "start_date": "2006-06",
      "completion_date": "2007-03",
      "has_results": false,
      "last_update_posted_date": "2013-02-15",
      "last_synced_at": "2026-06-11T05:35:17.383Z",
      "location_count": 1,
      "location_summary": "Irvine, California",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00333918"
    },
    {
      "nct_id": "NCT01344226",
      "title": "Clinical Outcomes and Evaluation of Lotemax 0.5% in Treatment of Ocular Inflammation Associated With Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Pseudophakia",
        "Inflammation"
      ],
      "interventions": [
        {
          "name": "loteprednol 0.5% ophthalmic solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Toyos Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 49,
      "start_date": "2011-04",
      "completion_date": "2013-09",
      "has_results": true,
      "last_update_posted_date": "2018-10-22",
      "last_synced_at": "2026-06-11T05:35:17.383Z",
      "location_count": 1,
      "location_summary": "Independence, Missouri",
      "locations": [
        {
          "city": "Independence",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01344226"
    },
    {
      "nct_id": "NCT02547623",
      "title": "Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Dexamethasone",
          "type": "DRUG"
        },
        {
          "name": "Prednisolone",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "ICON Bioscience Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "40 Years and older"
      },
      "enrollment_count": 194,
      "start_date": "2015-11-06",
      "completion_date": "2016-08-16",
      "has_results": true,
      "last_update_posted_date": "2018-08-21",
      "last_synced_at": "2026-06-11T05:35:17.383Z",
      "location_count": 11,
      "location_summary": "Glendora, California • Hemet, California • Laguna Hills, California + 8 more",
      "locations": [
        {
          "city": "Glendora",
          "state": "California"
        },
        {
          "city": "Hemet",
          "state": "California"
        },
        {
          "city": "Laguna Hills",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Edgewood",
          "state": "Kentucky"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02547623"
    },
    {
      "nct_id": "NCT02819908",
      "title": "Dropless™ vs. Less Drops™ Pharmaceutical Regimens After Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Intraocular Lens Associated Postoperative Inflammation"
      ],
      "interventions": [
        {
          "name": "Imprimis Dropless",
          "type": "DRUG"
        },
        {
          "name": "Imprimis Less Drops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Eye Center of North Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 25,
      "start_date": "2015-09",
      "completion_date": "2016-04",
      "has_results": true,
      "last_update_posted_date": "2020-03-09",
      "last_synced_at": "2026-06-11T05:35:17.383Z",
      "location_count": 1,
      "location_summary": "Panama City, Florida",
      "locations": [
        {
          "city": "Panama City",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02819908"
    },
    {
      "nct_id": "NCT04246801",
      "title": "Clobetasol Propionate Ophthalmic Nanoemulsion 0.05% for the Treatment of Inflammation and Pain Associated With Cataract Surgery (CLOSE-1)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cataract"
      ],
      "interventions": [
        {
          "name": "Clobetasol propionate",
          "type": "DRUG"
        },
        {
          "name": "Vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Salvat",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 250,
      "start_date": "2020-06-10",
      "completion_date": "2021-05-19",
      "has_results": true,
      "last_update_posted_date": "2022-12-22",
      "last_synced_at": "2026-06-11T05:35:17.383Z",
      "location_count": 22,
      "location_summary": "Chandler, Arizona • Beverly Hills, California • Glendora, California + 19 more",
      "locations": [
        {
          "city": "Chandler",
          "state": "Arizona"
        },
        {
          "city": "Beverly Hills",
          "state": "California"
        },
        {
          "city": "Glendora",
          "state": "California"
        },
        {
          "city": "Murrieta",
          "state": "California"
        },
        {
          "city": "Pasadena",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04246801"
    },
    {
      "nct_id": "NCT00521456",
      "title": "A Study of Ketorolac for the Treatment of Inflammation and Pain Associated With Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Cataract Extraction"
      ],
      "interventions": [
        {
          "name": "ketorolac eye drops",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Allergan",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 263,
      "start_date": "2007-10",
      "completion_date": "2008-03",
      "has_results": true,
      "last_update_posted_date": "2009-10-01",
      "last_synced_at": "2026-06-11T05:35:17.383Z",
      "location_count": 1,
      "location_summary": "San Diego, California",
      "locations": [
        {
          "city": "San Diego",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00521456"
    },
    {
      "nct_id": "NCT01847638",
      "title": "Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Cataract",
        "Retinal Edema",
        "Inflammation"
      ],
      "interventions": [
        {
          "name": "Prolensa (bromfenac 0.07%)",
          "type": "DRUG"
        },
        {
          "name": "Ilevro (nepafenac 0.3%)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Melissa Toyos",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 50,
      "start_date": "2013-04-01",
      "completion_date": "2018-08-23",
      "has_results": true,
      "last_update_posted_date": "2018-11-14",
      "last_synced_at": "2026-06-11T05:35:17.383Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01847638"
    }
  ]
}